News Posts List
The Making of a Hometown Hero
12/07/2016
His insights tell the story of more than a great sports legend, but that of a man with the strength of character to face kidney cancer head on and beat it in 1998.
Immunotherapy before surgery could dramatically improve cancer survival
12/06/2016
Dr Michele Teng, who led the study, said if they results were replicated in humans it could lead to widespread changes in oncology practices
Immunotherapy kills cancer, and organs too
12/06/2016
Priority is anti-tumor effects. Everything else, however severe, is considered the price worth paying.
FDA starts speedy review of Merck/Pfizer's PD-L1 inhibitor
12/05/2016
Pfizer and Merck KGaA have moved closer to bringing the fourth checkpoint inhibitor to the US market after the FDA granted a priority review for the drug in a rare form of skin cancer.
Therapeutic target in clear cell renal cancer
12/02/2016
Examination of the TCGA RNA-seq dataset also revealed widespread activation of NOTCH pathway in a large cohort of CCRCC samples.
Different Approaches to Adjuvant Therapy in RCC
12/01/2016
...these approaches allow oncologists to examine tissue samples and learn more about how these drugs affect the primary tumor - See more at: http://www.onclive.com/onclive-tv/dr-margulis-on-different-approaches-to-adjuvant-therapy-in-rcc#sthash.RO7Md4Zh.dpuf
New drug combo stops advanced kidney tumors
11/30/2016
The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer...
Onions and Garlic May Prevent Cancers
11/22/2016
Italian researchers found that people whose diets are rich in onions, garlic, and other alliums have a much lower risk of several types of cancer than those who avoid the pungent herbs.
New Links Between Diet, Cancer Risk
11/15/2016
Together, this research offers some of the strongest evidence to date of a link between diet and cancer, the study authors said
Survival of mRCC patients treated with AGS-003
11/08/2016
An update on two unusual cases from this Phase 2 study with intermediate risk mRCC, who obtained long term control of metastatic disease that is remarkably still ongoing nearly seven years after initiation of AGS-003 therapy.
News Feed